Treatment of severe chronic ocular graft-versus-host disease
Reviewed by Jonathan Chan

A retrospective study from Cologne, Germany, between November 2012 to March 2015, of 17 patients with graft-versus-host disease (GVHD) treated with 100% single use vials autologous serum eye drops in sealed system. Visual acuity, corneal staining, frequency of artificial tears, ocular symptoms and side-effects were analysed by questionnaire. After six month follow-up, significant improvement of visual acuity, corneal staining and ocular symptoms was reported. The frequency of artificial tears was reduced and no side-effects were reported. The cost of insurance compensation was up to 80%. The authors concluded the need for further prospective trials and different dilution of the serum in future studies.

Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from sealed manufacturing system: a retrospective cohort study.
Tahmaz V, Gehlsen U, Sauerbier L, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2017;101:322-6.